(AVTR) Avantor - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US05352A1007
Stock: Lab Supplies, Chemicals, Equipment, Services
Total Rating 29
Risk 84
Buy Signal -1.09
| Risk 5d forecast | |
|---|---|
| Volatility | 57.0% |
| Relative Tail Risk | -19.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.16 |
| Alpha | -67.26 |
| Character TTM | |
|---|---|
| Beta | 0.755 |
| Beta Downside | 0.400 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.89% |
| CAGR/Max DD | -0.39 |
EPS (Earnings per Share)
Revenue
Description: AVTR Avantor March 04, 2026
Avantor, Inc. (AVTR) supplies essential products and services to biopharma, healthcare, education, government, and advanced technology sectors globally.
The companys offerings include materials and consumables like chemicals, lab supplies, and customized single-use assemblies. This business model focuses on providing critical components for scientific research and manufacturing.
Avantor also provides equipment, such as filtration systems, incubators, and analytical instruments. Additionally, it offers services including onsite lab support, procurement, and biopharmaceutical material development, reflecting a comprehensive approach to supporting scientific and industrial operations.
The Life Sciences Tools & Services sub-industry, where Avantor operates, is characterized by its foundational role in drug discovery, development, and manufacturing.
For more detailed financial analysis, consider exploring Avantors profile on ValueRay.
Headlines to watch out for
- Biopharma research spending directly impacts Avantors consumables sales
- Global healthcare investment drives demand for equipment and services
- Supply chain disruptions increase raw material and logistics costs
- Regulatory changes in life sciences affect product development and sales
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -530.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.52 > 1.0 |
| NWC/Revenue: 16.37% < 20% (prev 2.05%; Δ 14.31% < -1%) |
| CFO/TA 0.05 > 3% & CFO 623.8m > Net Income -530.2m |
| Net Debt (3.58b) to EBITDA (138.7m): 25.82 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (679.3m) vs 12m ago -0.50% < -2% |
| Gross Margin: 32.65% > 18% (prev 0.34%; Δ 3.23k% > 0.5%) |
| Asset Turnover: 54.81% > 50% (prev 56.00%; Δ -1.19% > 0%) |
| Interest Coverage Ratio: -1.60 > 6 (EBITDA TTM 138.7m / Interest Expense TTM 169.8m) |
Altman Z'' 1.86
| A: 0.09 (Total Current Assets 2.45b - Total Current Liabilities 1.38b) / Total Assets 11.79b |
| B: 0.14 (Retained Earnings 1.67b / Total Assets 11.79b) |
| C: -0.02 (EBIT TTM -271.5m / Avg Total Assets 11.95b) |
| D: 0.91 (Book Value of Equity 5.64b / Total Liabilities 6.23b) |
| Altman-Z'' Score: 1.86 = BBB |
Beneish M -3.09
| DSRI: 1.08 (Receivables 1.07b/1.03b, Revenue 6.55b/6.78b) |
| GMI: 1.03 (GM 32.65% / 33.60%) |
| AQI: 0.95 (AQ_t 0.73 / AQ_t-1 0.76) |
| SGI: 0.97 (Revenue 6.55b / 6.78b) |
| TATA: -0.10 (NI -530.2m - CFO 623.8m) / TA 11.79b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of AVTR shares?
As of March 25, 2026, the stock is trading at USD 7.73 with a total of 9,636,252 shares traded.
Over the past week, the price has changed by -0.90%, over one month by -15.15%, over three months by -31.47% and over the past year by -53.12%.
Over the past week, the price has changed by -0.90%, over one month by -15.15%, over three months by -31.47% and over the past year by -53.12%.
Is AVTR a buy, sell or hold?
Avantor has received a consensus analysts rating of 3.76.
Therefor, it is recommend to hold AVTR.
- StrongBuy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.9 | 40.5% |
| Analysts Target Price | 10.9 | 40.5% |
AVTR Fundamental Data Overview March 21, 2026
P/E Forward = 8.2988
P/S = 0.7922
P/B = 0.9437
Revenue TTM = 6.55b USD
EBIT TTM = -271.5m USD
EBITDA TTM = 138.7m USD
Long Term Debt = 3.92b USD (from longTermDebt, last quarter)
Short Term Debt = 30.8m USD (from shortTermDebt, last quarter)
Debt = 3.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.58b USD (from netDebt column, last quarter)
Enterprise Value = 8.77b USD (5.19b + Debt 3.95b - CCE 365.4m)
Interest Coverage Ratio = -1.60 (Ebit TTM -271.5m / Interest Expense TTM 169.8m)
EV/FCF = 17.72x (Enterprise Value 8.77b / FCF TTM 495.0m)
FCF Yield = 5.64% (FCF TTM 495.0m / Enterprise Value 8.77b)
FCF Margin = 7.55% (FCF TTM 495.0m / Revenue TTM 6.55b)
Net Margin = -8.09% (Net Income TTM -530.2m / Revenue TTM 6.55b)
Gross Margin = 32.65% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.41b) / Revenue TTM)
Gross Margin QoQ = 31.49% (prev 32.42%)
Tobins Q-Ratio = 0.74 (Enterprise Value 8.77b / Total Assets 11.79b)
Interest Expense / Debt = 1.01% (Interest Expense 40.0m / Debt 3.95b)
Taxrate = 35.15% (28.4m / 80.8m)
NOPAT = -176.1m (EBIT -271.5m * (1 - 35.15%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 2.45b / Total Current Liabilities 1.38b)
Debt / Equity = 0.71 (Debt 3.95b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 25.82 (Net Debt 3.58b / EBITDA 138.7m)
Debt / FCF = 7.23 (Net Debt 3.58b / FCF TTM 495.0m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.44% (Net Income -530.2m / Total Assets 11.79b)
RoE = -9.02% (Net Income TTM -530.2m / Total Stockholder Equity 5.88b)
RoCE = -2.77% (EBIT -271.5m / Capital Employed (Equity 5.88b + L.T.Debt 3.92b))
RoIC = -1.78% (negative operating profit) (NOPAT -176.1m / Invested Capital 9.92b)
WACC = 5.21% (E(5.19b)/V(9.14b) * Re(8.67%) + D(3.95b)/V(9.14b) * Rd(1.01%) * (1-Tc(0.35)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 85.43% ; FCFF base≈573.8m ; Y1≈526.3m ; Y5≈469.9m
[DCF] Fair Price = 15.44 (EV 14.11b - Net Debt 3.58b = Equity 10.53b / Shares 682.1m; r=6.0% [WACC]; 5y FCF grow -10.37% → 3.0% )
EPS Correlation: -88.24 | EPS CAGR: -13.56% | SUE: 0.24 | # QB: 0
Revenue Correlation: -90.03 | Revenue CAGR: -4.15% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.20 | Chg7d=+0.000 | Chg30d=-0.036 | Revisions Net=-12 | Analysts=17
EPS current Year (2026-12-31): EPS=0.79 | Chg7d=-0.001 | Chg30d=-0.122 | Revisions Net=-16 | Growth EPS=-12.2% | Growth Revenue=-0.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg7d=-0.000 | Chg30d=-0.157 | Revisions Net=-8 | Growth EPS=+7.1% | Growth Revenue=+2.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 12 Down within 30d for Next Quarter)
P/S = 0.7922
P/B = 0.9437
Revenue TTM = 6.55b USD
EBIT TTM = -271.5m USD
EBITDA TTM = 138.7m USD
Long Term Debt = 3.92b USD (from longTermDebt, last quarter)
Short Term Debt = 30.8m USD (from shortTermDebt, last quarter)
Debt = 3.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.58b USD (from netDebt column, last quarter)
Enterprise Value = 8.77b USD (5.19b + Debt 3.95b - CCE 365.4m)
Interest Coverage Ratio = -1.60 (Ebit TTM -271.5m / Interest Expense TTM 169.8m)
EV/FCF = 17.72x (Enterprise Value 8.77b / FCF TTM 495.0m)
FCF Yield = 5.64% (FCF TTM 495.0m / Enterprise Value 8.77b)
FCF Margin = 7.55% (FCF TTM 495.0m / Revenue TTM 6.55b)
Net Margin = -8.09% (Net Income TTM -530.2m / Revenue TTM 6.55b)
Gross Margin = 32.65% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.41b) / Revenue TTM)
Gross Margin QoQ = 31.49% (prev 32.42%)
Tobins Q-Ratio = 0.74 (Enterprise Value 8.77b / Total Assets 11.79b)
Interest Expense / Debt = 1.01% (Interest Expense 40.0m / Debt 3.95b)
Taxrate = 35.15% (28.4m / 80.8m)
NOPAT = -176.1m (EBIT -271.5m * (1 - 35.15%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 2.45b / Total Current Liabilities 1.38b)
Debt / Equity = 0.71 (Debt 3.95b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 25.82 (Net Debt 3.58b / EBITDA 138.7m)
Debt / FCF = 7.23 (Net Debt 3.58b / FCF TTM 495.0m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.44% (Net Income -530.2m / Total Assets 11.79b)
RoE = -9.02% (Net Income TTM -530.2m / Total Stockholder Equity 5.88b)
RoCE = -2.77% (EBIT -271.5m / Capital Employed (Equity 5.88b + L.T.Debt 3.92b))
RoIC = -1.78% (negative operating profit) (NOPAT -176.1m / Invested Capital 9.92b)
WACC = 5.21% (E(5.19b)/V(9.14b) * Re(8.67%) + D(3.95b)/V(9.14b) * Rd(1.01%) * (1-Tc(0.35)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 85.43% ; FCFF base≈573.8m ; Y1≈526.3m ; Y5≈469.9m
[DCF] Fair Price = 15.44 (EV 14.11b - Net Debt 3.58b = Equity 10.53b / Shares 682.1m; r=6.0% [WACC]; 5y FCF grow -10.37% → 3.0% )
EPS Correlation: -88.24 | EPS CAGR: -13.56% | SUE: 0.24 | # QB: 0
Revenue Correlation: -90.03 | Revenue CAGR: -4.15% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.20 | Chg7d=+0.000 | Chg30d=-0.036 | Revisions Net=-12 | Analysts=17
EPS current Year (2026-12-31): EPS=0.79 | Chg7d=-0.001 | Chg30d=-0.122 | Revisions Net=-16 | Growth EPS=-12.2% | Growth Revenue=-0.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg7d=-0.000 | Chg30d=-0.157 | Revisions Net=-8 | Growth EPS=+7.1% | Growth Revenue=+2.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 12 Down within 30d for Next Quarter)